








Multiple Myeloma (MM)

Post Stem Cell
Transplant

BMT404
Open-Label
Non-Randomized
Multicenter Phase
II Study to Study
the Efficacy of
Talquetamab
(JNJ-64407564) &
Lenalidomide as
Post Stem Cell
Transplant
Maintenance in
Multiple Myeloma
(OPTIMMAL)

PI: Sidana
Sponsor: Stanford
University

KEY

	Pending		Optional Path		Extension Study
	Open for Enrollment	Link	Trial Posting		Immunotherapy
	Observational Study		Enrollment on Hold		